The U.S. Department of Defense plans to screen military service members for low testosterone starting later this year [1].
The initiative aims to evaluate how hormone levels impact combat readiness. However, the move comes amid a broader medical debate regarding who actually requires testosterone replacement therapy and whether routine screening is beneficial for healthy adults [1, 3].
Medical experts, including Dr. Mohit Khera, have raised concerns about the widespread use of hormone therapy [1]. Some practitioners said that most healthy men do not need routine testosterone tests [3]. This tension exists as social-media trends frequently portray testosterone therapy as a "fountain of youth," driving demand for treatments that may not be medically necessary [1, 2].
While the military intends to use screening to identify personnel who truly need therapy, some critics said the data may be misleading [1]. Evidence suggests that a low test result rarely explains the underlying cause of a symptom or provides a clear path for treatment [2].
The Department of Defense has not yet released the specific criteria it will use to determine which service members qualify for therapy following their screenings [1]. This lack of a standardized threshold remains a point of contention for those who believe the screenings could lead to over-treatment of healthy soldiers [2, 3].
Experts said that the biological markers of testosterone can fluctuate based on various factors. Because of this, a single screening may not provide a complete health profile for a service member [3].
“The U.S. Department of Defense plans to screen military service members for low testosterone starting later this year.”
The military's decision to implement hormone screening highlights a conflict between institutional goals for combat readiness and clinical guidelines for preventative medicine. If the Department of Defense adopts a broad screening approach without strict diagnostic thresholds, it risks medicalizing normal biological variations and increasing the prevalence of hormone therapy in a population where the long-term safety and efficacy of such treatments for healthy individuals remain debated.
